Paula Rodriguez-Otero, MD, PhD, discusses the promising results from the phase 3 PERSEUS trial in patients with newly diagnosed, transplant-eligible multiple myeloma.
Paula Rodriguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, discusses the promising results from the phase 3 PERSEUS trial (NCT03710603), a randomized, interventional, open-label, study comparing subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and daratumumab/lenalidomide maintenance in patients with newly diagnosed, transplant-eligible multiple myeloma.
According to Otero, this regimen significantly prolonged the rates of progression-free survival (PFS) in this patient population. At a median follow-up of 47.5 months, the 4-year PFS rate observed among patients treated with D-VRd was 84.3% vs 67.7% with VRd. This led to a 58% reduction in the risk of disease progression or death with the addition of the CD38 monoclonal antibody (HR, 0.42; 95% CI, 0.30-0.59; P <.0001). Further, the overall rate of complete response or better (≥CR) was 87.9% with D-VRd vs 70.1% with VRd (P <.0001).
These findings will likely change the standard of care for the treatment of patients with newly diagnosed multiple myeloma.
Transcription:
0:09 | This is a late breaker and also the 1 of the most relevant abstracts that was presented [at the 2023 ASH Annual Meeting] because this probably [and] clearly will change the standard of care for treatment of [patients with] newly diagnosed multiple myeloma that are candidates for transplant. The results presented by Dr. Sonneveld were very impressive, mostly because of the high rates of minimal residual disease in the D-VRd treatment arm.
0:43 | [This also led] to an improvement in PFS in these patients, and these are probably 1 of the higher rates of MRD negativity shown in the setting of the newly diagnosed frontline and transplant eligible candidates. I think that this is a very important abstract, a very important paper, and a very important treatment to give to all of our [patients with] newly diagnosed transplant eligible myeloma.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More